Avanafil use in patients with erectile dysfunction and co-morbidities: Clinical insights from multiple aetiologies - A case series.

Abstract

Erectile dysfunction (ED) is a prevalent medical problem affecting men globally, particularly those with co-morbidities such as cardiovascular disease, hypertension, dyslipidaemia and diabetes. This case series aimed to evaluate the effects of avanafil as a treatment option for patients with ED and other co-morbidities. Eight male patients from a family medicine clinic received either 100 mg or 200 mg avanafil based on their clinical indication. Erectile function was assessed using the International Index of Erectile Function-5 (IIEF-5) and Erection Hardness Score. The outcomes included changes in the IIEF-5 score upon avanafil treatment. Our findings demonstrated a significant increase in the 200 mg avanafil treatment group, with the IIEF-5 score increasing from 14.83±9.4 to 24.17±2.6 (P<0.05). However, no significant difference was observed in the 100 mg avanafil treatment group (P=0.7903) and the overall avanafil treatment group (100 mg + 200 mg avanafil; P=0.0501). No adverse events were reported among the patients. Avanafil is considered a potentially safe and effective treatment option for ED, particularly in individuals with co-morbidities.